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Here we report the synthesis and in vitro characterization of a redox-sensitive,
magnetically inducible nanoparticle carrier system based on the doxorubicin (DOX) drug
delivery model. Each quantal nanocarrier unit consists of a magnetite Fe3O4 nanoparticle
core that is further encapsulated in self-assembled micelles of the redox-responsive
polyethylene glycol derivative, DSPE-SS-mPEG. The nanocarrier system was prepared
using a combination of ultrasonication and dialysis to produce the microenvironment
sensitive delivery system. The final synthesized and DOX-loaded magnetic nanocarriers
had an average size of ∼150 nm when assembled with a 6.9% DOX payload. The
release rate of DOX from these redox-responsive magnetic nanocarriers was shown
to be accelerated in vitro when in the presence of glutathione (GSH). Furthermore, we
demonstrated that more redox-responsive magnetic nanocarriers could be taken up by
HeLa cells when a local magnetic field was applied. Once internalized within a cell,
the micelles of the outer nanocarrier complex were broken down in the presence of
higher concentrations of GSH, which accelerated the release of DOX. This produces a
particle with dual operating characteristics that can be controlled via a specific cellular
environment coupled with an exogenously applied signal in the form of a magnetic field
triggering release.
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INTRODUCTION
Chemotherapy is the most commonly used approach to treating cancer. Traditionally, the
chemotherapeutic agents (doxorubicin, paclitaxel, etc.) are systemically delivered through
intravenous injection. While this is often an effective approach and can successfully eliminate
malignant cell populations, treatment-associatedmorbidity is often significant (1). Quite frequently
this is a result of unintended action of the therapeutic agent at non-specific cellular targets causing
injury to healthy somatic cells in addition to the desired effect on malignant cells (2–6). Despite
this large unintended effect on healthy cells of the patient, chemotherapy remains a pillar of cancer
treatment due to its efficacy, particularly when used as part of a multimodal treatment plan. At the
intersection of the potency of chemotherapy as a curative agent and the extensive side effect
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profile causing wide-ranging cytotoxicity lays a rationale that
suggests transport of the chemotherapeutic agent directly to
the tumor site, which avoids systematic exposure, may alleviate
unintentional cytotoxic effects on healthy tissue. This concept
has existed in the medical literature for quite some time, but
only recently has progress in functionalization of mesoscopic
carrier particles led to significant progress in realizing this
goal. There are now several readily available preparations for
a medical oncology approach to cancer treatment that utilizes
nanotechnology, in the form of nanoparticle assemblies, to
facilitate the transport of highly potent cytotoxic compounds
more selectively into tumor sites with restricted systemic
circulating concentrations (7–9). These nanoparticles can be
constructed such that they resist degradation or internalization
except at the target tissue of interest where they are then able to
deposit and release their payload at the site of the malignancy
and not in healthy tissue (10–12). These particles can also
be used to focus energy from external radiative sources into
tumor masses acting to physically damage the cancerous cells in
addition to the chemical damage affected by the pharmacological
agent (13). This is an elegant solution to the problem of how
to transport chemotherapeutic drugs to the tumor site without
leakage and subsequently release a drug into the tumor-specific
microenvironment is an important issue that needs to be solved
in the treatment of cancer. The rise of nanotechnology has
provided a new set of tools for use in solving this problem of
targeted drug delivery (14–17).
The use of nanoparticles as a carrier vehicle for the targeted
delivery of chemotherapeutic drugs has the potential to greatly
reduce collateral damage to non-cancerous human tissues and
organs (18, 19). For example, by modifying the surface of a
nanoparticle with intelligent molecules, the nano drug carriers
can stimulate drug release in response to the particular micro-
environment of pathological tissues to reduce the incidence
of healthy cell damage and selectively kill cancer cells (20–
22). The study of nano drug carriers provides a new direction
for the delivery of care in addition to the traditional cancer
treatment approaches already in use and possesses significant
potential for future clinical applications (20, 23, 24). In this
study, we constructed spherical nanoparticle carriers containing
doxorubicin (an antineoplastic drug) with a diameter of about
150 nm.We provide functional data to demonstrate that the entry
of the drug carriers into HeLa cells can be enhanced in amagnetic
field and the release of the drug can be facilitated by elevating the
concentration of glutathione (GSH), resulting in the demise of
HeLa cells. As several cancer cells have high intracellular GSH
concentrations, using the constructed nanoparticle carriers may
achieve satisfying efficacy in killing cancer cells, while causing
only minor damage in normal tissue (25–27).
MATERIALS AND METHODS
Materials
The Fe3O4 nanoparticles were prepared using a thermal
decomposition method described previously (28). DSPE-SS-
mPEG 2000 was purchased from Xi’an Ruixi Biotechnology
Co. (Xi’an, China), Doxorubicin hydrochloride (DOX·HCl) and
GSH were purchased from Sigma-Aldrich (St. Louis, MO, USA),
dimethyl sulfoxide (DMSO) and triethylamine (TEA) were
obtained from Shanghai Chemical Co. (Shanghai, China) (29).
Human cervical adenocarcinoma (HeLa) cells were purchased
from the China Center for Type Culture Collection (Wuhan
University) and cultured in Dulbecco’s modified Eagle’s medium
(DMEM, Gibco Life, Grand Island, NY, USA) supplemented with
10% fetal bovine serum (FBS, HyClone, Logan, UT), 2× 10−3M
L-glutamine and 1% antibiotics mixture (10,000U of penicillin
and 10mg of streptomycin) (Gibco). The cells were incubated in
a humidified atmosphere containing 5% CO2 at 37
◦C.
Preparation of Nanocarriers
DOX-loaded redox-responsive magnetic nanocarriers were
prepared using an ultrasonication-dialysis method. Briefly,
DOX·HCl (10mg) was stirred in DMSO (5mL) with twice
the number of mole of TEA for 2 h to obtain the DOX base.
80mg of DSPE-SS-mPEG was added to the solution, which
was stirred at room temperature for another 2 h. Meanwhile,
the Fe3O4 nanoparticles (20mg) were dissolved in 10mL of
(tetrahydrofuran) THF. The above two solutions were mixed
and added to ultrapure water (25mL) with ultrasonication. The
mixed solution was then transferred into a dialysis tube and
dialyzed against ultrapure water for 48 h at room temperature.
Similarly, DOX-free nanocarriers were prepared using the above
mentioned protocol without the addition of DOX.
Characterization of Nanocarriers
The size of the nanocarriers in aqueous solution was measured
using a Zetasizer analyzer (Malvern Zetasizer Nano, Zen
3690+MPT2, Malvern, UK). Ultrastructural features and surface
geometry of the synthesized nanocarriers was observed by
transmission electron microscopy (TEM) (Tecnai G2 F20 S-
TWIN electron microscope, FEI company. the USA) at an
accelerating voltage of 200 kV.
DOX-loaded nanocarriers were dissolved in DMSO to
determine the total content of loaded drug. The DOX
content in DMSO was determined by high-performance liquid
chromatography (HPLC, Agilent) using a calibration curve
obtained from DOX/DMSO solutions containing a known
concentration of DOX.
For Fe3O4 content measurement, the weighed, freeze-dried
nanocarriers were digested in a 1M HCl solution. The resulting
digestion product was then analyzed for atomic species using
inductively coupled plasma-atomic emission spectroscopy (TCP-
AES, Thermo Electron, USA).
Redox-Triggered Disassembly of
Nanocarriers
The change in the size of redox-responsivemagnetic nanocarriers
in response to 20mMGSH in PBS (0.01M, pH 7.4) wasmeasured
using dynamic light scattering (DLS). Briefly, 20mM GSH was
added to 1.5mL of PBS containing nanocarriers within a glass
cell. The solution was then placed in a shaking water bath at
37◦C, oscillating at 150 rpm. At varying intervals following
agitation, the size of nanocarrier particles contained in solution
was assessed using DLS.
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In vitro Redox-Triggered Release of DOX
From DOX-Loaded Nanocarriers
The in vitro release profile of nanocarriers was investigated
using dialysis of DOX-loaded nanocarriers in two different
media: PBS or PBS supplemented with 20mM GSH. Each
solution was diluted to 1.5 mg/mL and 5mL of the solution
was transferred into a membrane tubing. The tubing with the
solution was immersed in a tube containing 50mL of the buffer
solution in a shaking water bath at 37◦C to acquire the “sink”
condition. At predetermined intervals, 20mL of the external
buffer was withdrawn and replaced with a fresh solution of
the corresponding buffer. The amount of DOX released was
determined using HPLC.
Cell TEM Imaging
For TEM imaging, HeLa cells were incubated with DOX-loaded
nanocarriers at a final DOX concentration of 5µg/mL in DMEM
for 2 h at 37◦C in the presence or absence of an externally applied
magnetic field. The culture medium was removed and the cells
were pre-fixed with 2.5% glutaraldehyde in PBS at 4◦C for 2 h
and post-fixed with 1% osmium tetroxide in PBS at 4◦C for
2 h. The cells were then dehydrated using serially increasing
concentrations of ethanol and flat embedded in Epon 812. After
polymerization at 60◦C for 48 h, ultrathin sections (60–80 nm)
were trimmed and further stained with uranyl acetate and lead
citrate. Micrographs of the stained samples were collected with
an FEI Tecnaio G220 TWIN Transmission Electron Microscope.
Cell Viability Assay
To evaluate the anti-tumor activity of DOX-loaded nanocarriers,
the cytotoxicity of DOX-loaded nanocarriers or free DOX against
HeLa cells was evaluated in vitro using the MTT assay. HeLa cells
were seeded into a 96-well plate at a density of 4.0× 103 cells/well
in 100 µL of complete DMEM. The cells were cultured for 24 h
at 37◦C in a 5% CO2 atmosphere. Subsequently, the cells were
incubated with DOX-loaded nanocarriers or free DOX for 24 h
at 37◦C with or without the presence of an external magnetic
field. DOX-loaded nanocarriers or free DOX were diluted in
complete DMEM to a final DOX concentration ranging from 0.4
to 40µg/mL. After the incubation, 10 µL of MTT solution (5
mg/mL in PBS 7.4) was added to each well and incubated for
4 h. The media with MTT solution was removed and 200 µL of
DMSO was added to dissolve the formazan crystals and further
incubated for 15min at 37◦C. The absorbance readings were
recorded using a microplate spectrophotometer (PowerWave
XS2, BioTek Instruments, USA) at a wavelength of 540 nm.
The cell viability was normalized to that of cells cultured in
complete DMEM. The dose-effect curves were plotted and data
are presented as the average± SD (n= 4).
Confocal Laser Scanning Microscopy
(CLSM) Observation
CLSM was used to examine the intracellular distribution of
DOX. HeLa cells were seeded on coverslips in the wells of a
24-well plate at a density of 4.0 × 104 cells/well in 1mL of
complete DMEM. The cells were incubated for 24 h at 37◦C in
TABLE 1 | Properties of DOX-free and DOX-loaded nanocarriers.
DOX-free nanocarriers DOX-loaded nanocarriers
Size
(nm)
PDI Fe content
(wt%)
Size
(nm)
PDI Fe content
(wt%)
PLC
(wt%)
131 0.26 14.7 150 0.19 13.3 4.6
a 5% CO2 atmosphere. The cells were incubated with DOX-
loaded nanocarriers at a final DOX concentration of 5µg/mL
in DMEM for 2 h at 37◦C with or without an external magnetic
field. After removal of the medium, the cells were washed three
times with cold PBS, fixed with 1mL of 4% paraformaldehyde
for 30min at 4◦C, and stained with 2-(4-amidinophenyl)-6-
indolecarbamidine dihydrochloride (DAPI, Roche) for 10min.
Finally, the slides were mounted with 10% glycerol solution
and viewed using a LeicaTCS SP8 (Leica Microscopy Systems
Ltd., Germany).
RESULTS AND DISCUSSION
Characterization of Nanocarriers
The particle size and polydispersity (PDI) of DOX-free or
DOX-loaded nanocarriers were determined by DLS, as shown
in Table 1. The prepared DOX-free nanocarriers and DOX-
loaded nanocarriers (Figure 1A) were determined to be 131
or 150 nm respectively, with a narrow size distribution,
thereby making them suitable as anticancer drug carriers. The
morphology of the redox-responsive magnetic nanocarriers was
observed using TEM. Figure 1B shows the morphology of the
nanocarriers. Because DSPE-SS-mPEG does not significantly
attenuate electron scattering under TEM, nanocarriers are largely
present as isolated clusters of Fe3O4 nanoparticles with a
spherical shape. The drug loading content values of DOX-loaded
nanocarriers was 4.6% (Table 1). Whereas, the Fe content of
DOX-free or DOX-loaded nanocarriers was 14.7 and 13.3%,
respectively (Table 1).
The Redox-Responsive Stability of
Nanocarriers
Disulfide linkages are known to be readily reduced into free
thiols in the presence of reducing agents. To demonstrate the
responsiveness, the size change of redox-responsive magnetic
nanocarriers in response to 20mM GSH in PBS was measured
by DLS. Figure 2 shows that the average size of the nanocarriers
gradually increased within the first 15min after the addition
of GSH. The size increased from 131 to 340 nm in 15min,
indicating the detachment of hydrophilic PEG shells from the
nanocarriers and the enhanced hydrophobic interaction of the
inner core. After 1 h, two populations at 547 nm and 1,038 nm
were observed, however, after 3 h, the complete destruction of the
nanocarriers was observed, and no nanoparticles were detected in
the solution.
In vitro Redox-Responsive DOX Release
The drug release behavior of the DOX-loaded nanocarriers was
investigated in PBS at 37◦C in the presence or absence of
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FIGURE 1 | The size distribution by DLS (A), and TEM micrographs (B) of redox-responsive magnetic nanocarriers.
FIGURE 2 | The size change of redox-responsive magnetic nanocarriers in
response to 20mM GSH in PBS determined by DLS measurement.
GSH (20mM). Figure 3 shows the accumulative drug release
profiles as a function of time. Figure 3 demonstrates that the
release of DOX from nanocarriers was markedly correlated with
the presence or absence of GSH. The release of DOX from
nanocarriers was accelerated by the addition of GSH to the
media. In the presence of 20mM GSH, nanocarriers rapidly
released DOX, such that 93.8% of the DOX dose was released
within 24 h. However, only 28.7% of DOX was released in
the absence of GSH. This difference might be due to cleavage
of disulfide bonds, thereby causing the destruction of the
nanocarriers and the accelerated release of encapsulated DOX.
Cell TEM Imaging
The rapid accumulation of DOX-loaded nanocarriers was found
to be magnetically inducible in vitro and was characterized using
TEM. When HeLa cells were incubated for 2 h with DOX-loaded
FIGURE 3 | Redox-triggered release of DOX from redox-responsive magnetic
nanocarriers in PBS with or without 20mM GSH. The standard deviation for
each data point was averaged over three samples (n = 3).
nanocarriers in either the presence or absence of a magnetic field,
the accumulation of nanocarriers was found to be altered. TEM
images demonstrating this observation are shown in Figure 4.
The heavily electro-dense iron-containing nanoparticles are
reproduced in the TEM images as a significantly darker
region in contrast to the cellular environment, which facilitated
identification of relative particle density between groups. The
number of magnetic nanoparticles in cells significantly increased
when a magnetic field was applied (Figure 4B), suggesting that
the presence of a magnetic field enhanced the accumulation of
nanocarriers in cells.
Cell Viability Assay
The in vitro cytotoxicity of DOX-loaded nanocarriers and free
DOX was evaluated using the MTT assay. Figure 5 shows the
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FIGURE 4 | TEM images of HeLa cells incubated with DOX-loaded nanocarriers in the absence (A) or presence (B) of a magnetic field. Scale bar is 1µm.
resulting levels of observed cytotoxicity measured as a function
of DOX concentration from 0.4 to 40µg/mL. All test conditions
exhibited a dose-dependent cytotoxic effect of the treatment on
the population of viable and metabolically active HeLa cells.
DOX-loaded nanocarriers exhibited lower cytotoxicity to HeLa
cells with or without the magnetic field, as compared to free DOX
at the same DOX dose (Figure 5A). As a control experiment, we
performed a group of experiments using nanocarriers without
DOX and examined cytotoxicity under magnetic and non-
magnetic conditions, suggesting that the nanocarriers alone did
not exhibit cytotoxicity (Figure 5B). Given that DOX is a small
molecule, it can be quickly transported into cells and enter
nuclei by passive diffusion. Furthermore, we found that the
presence of a local magnetic field could significantly increase
the cytotoxicity of DOX-loaded nanocarriers. This process
may be due to the magnetic field increasing cellular uptake
of nanocarriers, and once internalized, the redox-responsive
nanocarriers are destroyed by high levels of GSH. The DOX
is then rapidly released from the destroyed redox-responsive
nanocarriers. Taken together these results indicate that the DOX-
loaded nanocarriers can achieve both magnetic targeting and
reduction-sensitive release simultaneously.
In vitro Cellular Uptake of DOX-Loaded
Nanocarriers
The cellular uptake of the nanocarriers and the intracellular
location of the encapsulated DOX was monitored by CLSM in
HeLa cells. The nuclei of HeLa cells were stained with DAPI,
which presented blue fluorescence to distinguish from the red
fluorescence of the labeled DOX. Figure 6 shows CLSM images
of HeLa cells incubated with DOX-loaded nanocarriers for 2 h
with or without magnet field treatment. As shown in Figure 6, we
found that cells incubated with DOX-loaded nanocarriers with
applied magnetic field demonstrated stronger DOX fluorescence
compared to no applied magnetic field. This phenomenon is
primarily a result of the magnetic field increase in the cellular
uptake of the DOX-loaded nanocarriers. Our results indicate that
these nanocarriers are responsive to either magnetic or redox
stimulated activation and are therefore suitable for application as
anticancer drug carriers.
FIGURE 5 | Cytotoxicity of DOX-loaded magnetic nanocarriers and free DOX
in HeLa cells with or without magnetic field after incubation for 24 h (A). (B) In
control experiments, we examined cytotoxicity using magnetic nanocarriers
alone with or without magnetic field after incubation for 24 h, and found no
cytotoxicity. The standard deviation for each data point was averaged over
four samples (n = 4) for (A,B).
CONCLUSION
In this article, we use the amphiphilic copolymer DSPE-SS-
mPEG, which is connected by disulfide bonds. Afterward, the
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FIGURE 6 | CLSM images of HeLa cells after treatment with DOX-loaded magnetic nanocarriers for 2 h in the absence (A) or presence (B) of a magnetic field. Scale
bar is 15µm.
magnetic Fe3O4 nanoparticles and the hydrophobic drug are
made by the self-assembly of the amphiphilic copolymer. DOX is
encapsulated in the amphiphilic copolymer to form a magnetic
nano drug controlled release system which is sensitive and
responds to a reducing environment. This controlled release
system can dissociate the disulfide bonds in the presence
of dithiothreitol, thereby triggering the release system to
disintegrate and expel the drug.
When the DOX-loaded nanocarrier is transported into
the cell, intracellular GSH breaks the disulfide bonds,
resulting in the disintegration of the transport system and
the release of DOX. It is a well-designed enzyme-responsive
magnetic-field controlled release system and provides a new
foundation for building an efficient and safe nanoscale drug
delivery system.
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